{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T15:33:11Z","timestamp":1790004791359,"version":"4.0.1"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2013,3,15]],"date-time":"2013-03-15T00:00:00Z","timestamp":1363305600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/2.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diabetologia"],"published-print":{"date-parts":[[2013,5]]},"DOI":"10.1007\/s00125-013-2856-6","type":"journal-article","created":{"date-parts":[[2013,3,14]],"date-time":"2013-03-14T06:37:35Z","timestamp":1363243055000},"page":"973-984","source":"Crossref","is-referenced-by-count":141,"title":["Estimating the effect of sulfonylurea on HbA1c in diabetes: a systematic review and meta-analysis"],"prefix":"10.1007","volume":"56","author":[{"given":"J. A.","family":"Hirst","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. J.","family":"Farmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Dyar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T. W. C.","family":"Lung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. J.","family":"Stevens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,3,15]]},"reference":[{"key":"2856_CR1","unstructured":"NICE (2008) CG66 type 2 diabetes: full guideline. In: NICE clinical guideline 66. www.nice.org.uk\/nicemedia\/pdf\/CG66NICEGuideline.pdf"},{"issue":"302","key":"2856_CR2","first-page":"e301","volume":"125","author":"NR Desai","year":"2012","unstructured":"Desai NR, Shrank WH, Fischer MA et al (2012) Patterns of medication initiation in newly diagnosed diabetes mellitus: quality and cost implications. Am J Med 125(302):e301\u2013e307","journal-title":"Am J Med"},{"key":"2856_CR3","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1055\/s-2007-979837","volume":"28","author":"F Ashcroft","year":"1996","unstructured":"Ashcroft F (1996) Mechanisms of the glycaemic effects of sulfonylureas. Horm Metab Res 28:456\u2013463","journal-title":"Horm Metab Res"},{"key":"2856_CR4","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s00125-008-1157-y","volume":"52","author":"DM Nathan","year":"2009","unstructured":"Nathan DM, Buse JB, Davidson MB et al (2009) Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 52:17\u201330","journal-title":"Diabetologia"},{"key":"2856_CR5","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1056\/NEJM199508313330902","volume":"333","author":"RA DeFronzo","year":"1995","unstructured":"DeFronzo RA, Goodman AM (1995) Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group. N Engl J Med 333:541\u2013549","journal-title":"N Engl J Med"},{"key":"2856_CR6","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.2337\/dc09-1727","volume":"33","author":"D Sherifali","year":"2010","unstructured":"Sherifali D, Nerenberg K, Pullenayegum E, Cheng JE, Gerstein HC (2010) The effect of oral antidiabetic agents on A1C levels: a systematic review and meta-analysis. Diabetes Care 33:1859\u20131864","journal-title":"Diabetes Care"},{"key":"2856_CR7","doi-asserted-by":"crossref","first-page":"389","DOI":"10.2337\/dc06-1789","volume":"30","author":"AS Gangji","year":"2007","unstructured":"Gangji AS, Cukierman T, Gerstein HC, Goldsmith CH, Clase CM (2007) A systematic review and meta-analysis of hypoglycemia and cardiovascular events: a comparison of glyburide with other secretagogues and with insulin. Diabetes Care 30:389\u2013394","journal-title":"Diabetes Care"},{"key":"2856_CR8","doi-asserted-by":"crossref","first-page":"45","DOI":"10.7326\/0003-4819-115-1-45","volume":"115","author":"AL Peters","year":"1991","unstructured":"Peters AL, Davidson MB (1991) Insulin plus a sulfonylurea agent for treating type 2 diabetes. Ann Intern Med 115:45\u201353","journal-title":"Ann Intern Med"},{"key":"2856_CR9","doi-asserted-by":"crossref","first-page":"953","DOI":"10.2337\/diacare.15.8.953","volume":"15","author":"JA Pugh","year":"1992","unstructured":"Pugh JA, Wagner ML, Sawyer J, Ramirez G, Tuley M, Friedberg SJ (1992) Is combination sulfonylurea and insulin therapy useful in NIDDM patients? A metaanalysis. Diabetes Care 15:953\u2013959","journal-title":"Diabetes Care"},{"key":"2856_CR10","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1111\/j.1464-5491.2010.02941.x","volume":"27","author":"RA DeFronzo","year":"2010","unstructured":"DeFronzo RA, Stonehouse AH, Han J, Wintle ME (2010) Relationship of baseline HbA1c and efficacy of current glucose-lowering therapies: a meta-analysis of randomized clinical trials. Diabet Med 27:309\u2013317","journal-title":"Diabet Med"},{"key":"2856_CR11","doi-asserted-by":"crossref","first-page":"597","DOI":"10.2337\/diacare.20.4.597","volume":"20","author":"DC Simonson","year":"1997","unstructured":"Simonson DC, Kourides IA, Feinglos M, Shamoon H, Fischette CT (1997) Efficacy, safety, and dose\u2013response characteristics of glipizide gastrointestinal therapeutic system on glycemic control and insulin secretion in NIDDM: Results of two multicenter, randomized, placebo-controlled clinical trials. Diabetes Care 20:597\u2013606","journal-title":"Diabetes Care"},{"key":"2856_CR12","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1002\/sim.1186","volume":"21","author":"JP Higgins","year":"2002","unstructured":"Higgins JP, Thompson SG (2002) Quantifying heterogeneity in a meta-analysis. Stat Med 21:1539\u20131558","journal-title":"Stat Med"},{"key":"2856_CR13","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","volume":"315","author":"M Egger","year":"1997","unstructured":"Egger M, Davey Smith G, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315:629\u2013634","journal-title":"BMJ"},{"key":"2856_CR14","unstructured":"Higgins JPT, Green S (eds) (2005) Cochrane handbook for systematic reviews of interventions 4.2.4 [updated March 2005]. In: The Cochrane Library (Issue 2). Wiley, Chichester"},{"key":"2856_CR15","doi-asserted-by":"crossref","first-page":"42","DOI":"10.2337\/diacare.13.3.42","volume":"13","author":"R Pasmantier","year":"1990","unstructured":"Pasmantier R, Chaiken RL, Hirsch SR, Lebovitz HE (1990) Metabolic effects of combination glipizide and human proinsulin treatment in NIDDM. Diabetes Care 13:42\u201346","journal-title":"Diabetes Care"},{"key":"2856_CR16","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.2337\/diacare.21.9.1462","volume":"21","author":"ES Horton","year":"1998","unstructured":"Horton ES, Whitehouse F, Ghazzi MN, Venable TC, Whitcomb RW (1998) Troglitazone in combination with sulfonylurea restores glycemic control in patients with type 2 diabetes. The Troglitazone Study Group. Diabetes Care 21:1462\u20131469","journal-title":"Diabetes Care"},{"key":"2856_CR17","unstructured":"British National Formulary (2010) BMJ Group and Pharmaceutical Press, London"},{"key":"2856_CR18","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.diabres.2004.09.002","volume":"68","author":"M Feinglos","year":"2005","unstructured":"Feinglos M, Dailey G, Cefalu W et al (2005) Effect on glycemic control of the addition of 2.5\u00a0mg glipizide GITS to metformin in patients with T2DM. Diabetes Res Clin Pract 68:167\u2013175","journal-title":"Diabetes Res Clin Pract"},{"key":"2856_CR19","first-page":"1","volume":"14","author":"N Waugh","year":"2010","unstructured":"Waugh N, Cummins E, Royle P et al (2010) Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation. Health Tech Assess 14:1\u2013248","journal-title":"Health Tech Assess"},{"issue":"Suppl 3","key":"2856_CR20","doi-asserted-by":"crossref","first-page":"18","DOI":"10.2337\/diacare.13.3.18","volume":"13","author":"A Melander","year":"1990","unstructured":"Melander A, Lebovitz HE, Faber OK (1990) Sulfonylureas. Why, which, and how? Diabetes Care 13(Suppl 3):18\u201325","journal-title":"Diabetes Care"},{"key":"2856_CR21","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1111\/j.1742-1241.2009.02292.x","volume":"64","author":"IW Campbell","year":"2010","unstructured":"Campbell IW (2010) Comparing the actions of older and newer therapies on body weight: to what extent should these effects guide the selection of antidiabetic therapy? Int J Clin Pract 64:791\u2013801","journal-title":"Int J Clin Pract"},{"key":"2856_CR22","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1136\/bmj.309.6957.780","volume":"309","author":"JM Bland","year":"1994","unstructured":"Bland JM, Altman DG (1994) Statistics notes: some examples of regression towards the mean. BMJ 309:780","journal-title":"BMJ"},{"key":"2856_CR23","first-page":"952","volume":"16","author":"RA Camerini-Davalos","year":"1994","unstructured":"Camerini-Davalos RA, Bloodworth J, Velasco CA, Reddi AS (1994) Effect of insulin-glipizide combination on skeletal muscle capillary basement membrane width in diabetic patients. Clin Ther 16:952\u2013961","journal-title":"Clin Ther"},{"key":"2856_CR24","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1046\/j.1463-1326.2003.00239.x","volume":"5","author":"S Fischer","year":"2003","unstructured":"Fischer S, Patzak A, Reitzsch H et al (2003) Influence of treatment with acarbose or glibenclamide on insulin sensitivity in type 2 diabetic patients. Diabetes Obes Metabol 5:38\u201344","journal-title":"Diabetes Obes Metabol"},{"key":"2856_CR25","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1111\/j.1742-1241.2009.02265.x","volume":"64","author":"B Gallwitz","year":"2010","unstructured":"Gallwitz B, Vaag A, Falahati A, Madsbad S (2010) Adding liraglutide to oral antidiabetic drug therapy: onset of treatment effects over time. Int J Clin Pract 64:267\u2013276","journal-title":"Int J Clin Pract"},{"key":"2856_CR26","doi-asserted-by":"crossref","first-page":"4993","DOI":"10.1210\/jc.2010-0449","volume":"95","author":"M Zeller","year":"2010","unstructured":"Zeller M, Danchin N, Simon D et al (2010) Impact of type of preadmission sulfonylureas on mortality and cardiovascular outcomes in diabetic patients with acute myocardial infarction. J Clin Endocrinol Metab 95:4993\u20135002","journal-title":"J Clin Endocrinol Metab"},{"key":"2856_CR27","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1001\/jama.1971.03190220020005","volume":"218","author":"MG Goldner","year":"1971","unstructured":"Goldner MG, Knatterud GL, Prout TE (1971) Effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. 3. Clinical implications of UGDP results. JAMA 218:1400\u20131410","journal-title":"JAMA"},{"key":"2856_CR28","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1136\/bmj.321.7258.412","volume":"321","author":"AI Adler","year":"2000","unstructured":"Adler AI, Stratton IM, Neil HA et al (2000) Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ 321:412\u2013419","journal-title":"BMJ"},{"key":"2856_CR29","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1056\/NEJMoa066224","volume":"355","author":"SE Kahn","year":"2006","unstructured":"Kahn SE, Haffner SM, Heise MA et al (2006) Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 355:2427\u20132443","journal-title":"N Engl J Med"},{"key":"2856_CR30","doi-asserted-by":"crossref","first-page":"466","DOI":"10.2337\/diabetes.44.4.466","volume":"44","author":"MA Banerji","year":"1995","unstructured":"Banerji MA, Chaiken RL, Lebovitz HE (1995) Prolongation of near-normoglycemic remission in black NIDDM subjects with chronic low-dose sulfonylurea treatment. Diabetes 44:466\u2013470","journal-title":"Diabetes"},{"key":"2856_CR31","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1016\/S0140-6736(11)61879-5","volume":"379","author":"CF Burant","year":"2012","unstructured":"Burant CF, Viswanathan P, Marcinak J et al (2012) TAK-875 versus placebo or glimepiride in type 2 diabetes mellitus: a phase 2, randomised, double-blind, placebo-controlled trial. Lancet 379:1403\u20131411","journal-title":"Lancet"},{"key":"2856_CR32","unstructured":"Damsgaard EM, Faber O, Froland A, Iversen S (1982) Fasting blood glucose, glycohaemoglobin and urinary glucose excretion in non-insulin-dependent patients with diabetes mellitus (NIDDM). Ugeskrift for Laeger 144:2342\u20132344 [article in Danish]"},{"key":"2856_CR33","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1053\/meta.2001.21032","volume":"50","author":"P Ebeling","year":"2001","unstructured":"Ebeling P, Teppo AM, Koistinen HA, Koivisto VA (2001) Concentration of the complement activation product, acylation-stimulating protein, is related to C-reactive protein in patients with type 2 diabetes. Metab Clin Exp 50:283\u2013287","journal-title":"Metab Clin Exp"},{"key":"2856_CR34","doi-asserted-by":"crossref","first-page":"849","DOI":"10.2337\/diacare.19.8.849","volume":"19","author":"RB Goldberg","year":"1996","unstructured":"Goldberg RB, Holvey SM, Schneider J (1996) A dose\u2013response study of glimepiride in patients with NIDDM who have previously received sulfonylurea agents. The Glimepiride Protocol #201 Study Group. Diabetes Care 19:849\u2013856","journal-title":"Diabetes Care"},{"key":"2856_CR35","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.2337\/diacare.19.11.1194","volume":"19","author":"J Rosenstock","year":"1996","unstructured":"Rosenstock J, Samols E, Muchmore DB, Schneider J (1996) Glimepiride, a new once-daily sulfonylurea. A double-blind placebo-controlled study of NIDDM patients. Glimepiride Study Group. Diabetes Care 19:1194\u20131199","journal-title":"Diabetes Care"},{"key":"2856_CR36","doi-asserted-by":"crossref","first-page":"687","DOI":"10.2337\/diacare.20.5.687","volume":"20","author":"P Segal","year":"1997","unstructured":"Segal P, Feig PU, Schernthaner G et al (1997) The efficacy and safety of miglitol therapy compared with glibenclamide in patients with NIDDM inadequately controlled by diet alone. Diabetes Care 20:687\u2013691","journal-title":"Diabetes Care"},{"key":"2856_CR37","doi-asserted-by":"crossref","first-page":"84","DOI":"10.2337\/dc08-1355","volume":"32","author":"M Nauck","year":"2009","unstructured":"Nauck M, Frid A, Hermansen K et al (2009) Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study. Diabetes Care 32:84\u201390","journal-title":"Diabetes Care"},{"key":"2856_CR38","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1111\/j.1463-1326.2009.01158.x","volume":"11","author":"J Jendle","year":"2009","unstructured":"Jendle J, Nauck MA, Matthews DR et al (2009) Weight loss with liraglutide, a once-daily human glucagon-like peptide-1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue. Diabetes Obes Metabol 11:1163\u20131172","journal-title":"Diabetes Obes Metabol"},{"key":"2856_CR39","first-page":"106","volume":"7","author":"J Goldman","year":"1984","unstructured":"Goldman J, Tamayo RC, Whitehouse FW, Kahkonen DM (1984) Effect of glyburide on metabolic control and insulin binding in insulin-dependent diabetes mellitus. Diabetes Care 7:106\u2013112","journal-title":"Diabetes Care"},{"key":"2856_CR40","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1177\/106002809202600601","volume":"26","author":"JG Gums","year":"1992","unstructured":"Gums JG, Curry J, de Oca GM, Skluth HA, Reynolds LR (1992) Treatment of type I diabetes with a combination of glyburide and insulin. Ann Pharmacother 26:757\u2013762","journal-title":"Ann Pharmacother"},{"key":"2856_CR41","doi-asserted-by":"crossref","first-page":"545","DOI":"10.2337\/diacare.10.5.545","volume":"10","author":"M Gutniak","year":"1987","unstructured":"Gutniak M, Karlander SG, Efendic S (1987) Glyburide decreases insulin requirement, increases beta-cell response to mixed meal, and does not affect insulin sensitivity: effects of short- and long-term combined treatment in secondary failure to sulfonylurea. Diabetes Care 10:545\u2013554","journal-title":"Diabetes Care"},{"key":"2856_CR42","doi-asserted-by":"crossref","first-page":"963","DOI":"10.2337\/diacare.14.11.963","volume":"14","author":"SG Karlander","year":"1991","unstructured":"Karlander SG, Gutniak MK, Efendic S (1991) Effects of combination therapy with glyburide and insulin on serum lipid levels in NIDDM patients with secondary sulfonylurea failure. Diabetes Care 14:963\u2013967","journal-title":"Diabetes Care"},{"key":"2856_CR43","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1001\/archinte.1988.00380080043014","volume":"148","author":"UM Kabadi","year":"1988","unstructured":"Kabadi UM, Birkenholz MR (1988) Improved metabolic control in insulin-dependent diabetes mellitus with insulin and tolazamide. Arch Intern Med 148:1745\u20131749","journal-title":"Arch Intern Med"},{"key":"2856_CR44","unstructured":"Kabadi UM, McCoy S, Birkenholz M, Kabadi M (1995) More uniform diurnal blood glucose control and a reduction in daily insulin dosage on addition of glibenclamide to insulin in type 1 diabetes mellitus: role of enhanced insulin sensitivity. Diab Med J Brit Diabet Assoc: 880\u2013884"},{"key":"2856_CR45","first-page":"93","volume":"16","author":"H Leblanc","year":"1990","unstructured":"Leblanc H, Thote A, Chatellier G, Passa P (1990) Effect of glipizide on glycemic control and peripheral insulin sensitivity in type 1 diabetics. Diabete et Metabolisme 16:93\u201397","journal-title":"Diabete et Metabolisme"},{"key":"2856_CR46","doi-asserted-by":"crossref","first-page":"379","DOI":"10.2337\/diacare.12.6.379","volume":"12","author":"MS Lewitt","year":"1989","unstructured":"Lewitt MS, Yu VK, Rennie GC et al (1989) Effects of combined insulin-sulfonylurea therapy in type II patients. Diabetes Care 12:379\u2013383","journal-title":"Diabetes Care"},{"key":"2856_CR47","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1046\/j.1464-5491.1999.00170.x","volume":"16","author":"T Lindstrom","year":"1999","unstructured":"Lindstrom T, Nystrom FH, Olsson AG, Ottosson AM, Arnqvist HJ (1999) The lipoprotein profile differs during insulin treatment alone and combination therapy with insulin and sulphonylureas in patients with Type 2 diabetes mellitus. Diabet Med 16:820\u2013826","journal-title":"Diabet Med"},{"key":"2856_CR48","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1111\/j.0954-6820.1988.tb15783.x","volume":"223","author":"PE Lins","year":"1988","unstructured":"Lins PE, Lundblad S, Persson-Trotzig E, Adamson U (1988) Glibenclamide improves the response to insulin treatment in non-insulin-dependent diabetics with second failure to sulfonylurea therapy. Acta Med Scand 223:171\u2013179","journal-title":"Acta Med Scand"},{"key":"2856_CR49","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1097\/00000441-199203000-00003","volume":"303","author":"M Riddle","year":"1992","unstructured":"Riddle M, Hart J, Bingham P, Garrison C, McDaniel P (1992) Combined therapy for obese type 2 diabetes: suppertime mixed insulin with daytime sulfonylurea. Am J Med Sci 303:151\u2013156","journal-title":"Am J Med Sci"},{"key":"2856_CR50","doi-asserted-by":"crossref","first-page":"623","DOI":"10.2337\/diacare.12.9.623","volume":"12","author":"MC Riddle","year":"1989","unstructured":"Riddle MC, Hart JS, Bouma DJ, Phillipson BE, Youker G (1989) Efficacy of bedtime NPH insulin with daytime sulfonylurea for subpopulation of type II diabetic subjects. Diabetes Care 12:623\u2013629","journal-title":"Diabetes Care"},{"key":"2856_CR51","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.2337\/diacare.21.7.1052","volume":"21","author":"MC Riddle","year":"1998","unstructured":"Riddle MC, Schneider J (1998) Beginning insulin treatment of obese patients with evening 70\/30 insulin plus glimepiride versus insulin alone. Glimepiride Combination Group. Diabetes Care 21:1052\u20131057","journal-title":"Diabetes Care"},{"key":"2856_CR52","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.1001\/jama.1987.03390180059023","volume":"257","author":"DS Schade","year":"1987","unstructured":"Schade DS, Mitchell WJ, Griego G (1987) Addition of sulfonylurea to insulin treatment in poorly controlled type II diabetes. A double-blind, randomized clinical trial. JAMA 257:2441\u20132445","journal-title":"JAMA"},{"key":"2856_CR53","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1007\/BF00290586","volume":"31","author":"S Stenman","year":"1988","unstructured":"Stenman S, Groop PH, Saloranta C, Totterman KJ, Fyhrqvist F, Groop L (1988) Effects of the combination of insulin and glibenclamide in type 2 (non-insulin-dependent) diabetic patients with secondary failure to oral hypoglycaemic agents. Diabetologia 31:206\u2013213","journal-title":"Diabetologia"},{"key":"2856_CR54","doi-asserted-by":"crossref","first-page":"344","DOI":"10.4158\/EP.3.6.344","volume":"3","author":"CA Stuart","year":"1997","unstructured":"Stuart CA, Gilkison CR, Carlson RF (1997) Effect of adding a sulfonylurea in patients with non-insulin-dependent diabetes mellitus previously well controlled with insulin. Endocr Pract 3:344\u2013348","journal-title":"Endocr Pract"},{"key":"2856_CR55","doi-asserted-by":"crossref","first-page":"549","DOI":"10.2337\/diacare.24.3.549","volume":"24","author":"L Ryysy","year":"2001","unstructured":"Ryysy L, Yki-Jarvinen H (2001) Improvement of glycemic control by 1\u00a0year of insulin therapy leads to a sustained decrease in sE-selectin concentrations in type 2 diabetes. Diabetes Care 24:549\u2013554","journal-title":"Diabetes Care"},{"key":"2856_CR56","doi-asserted-by":"crossref","first-page":"169","DOI":"10.7326\/0003-4819-118-3-199302010-00002","volume":"118","author":"S Stenman","year":"1993","unstructured":"Stenman S, Melander A, Groop PH, Groop LC (1993) What is the benefit of increasing the sulfonylurea dose? Ann Intern Med 118:169\u2013172","journal-title":"Ann Intern Med"}],"container-title":["Diabetologia"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00125-013-2856-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00125-013-2856-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00125-013-2856-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,2,26]],"date-time":"2019-02-26T14:11:56Z","timestamp":1551190316000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00125-013-2856-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,3,15]]},"references-count":56,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2013,5]]}},"alternative-id":["2856"],"URL":"https:\/\/doi.org\/10.1007\/s00125-013-2856-6","relation":{},"ISSN":["0012-186X","1432-0428"],"issn-type":[{"value":"0012-186X","type":"print"},{"value":"1432-0428","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,3,15]]}}}